BSc3094

BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD) In Vivo BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau . BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70% . BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 3 mg/kg Administration: I.v. Result: Direct intraventricular administration reduced sarkosyl-insoluble Tau. Animal Model: rTg4510 mice Dosage: 0.075~1.5 mM Administration: Intraventricular administration Result: Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%. Form:Solid IC50& Target:Tau aggregation

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet